Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: Final results of the Japan Clinical Oncology Group trial JCOG9206-2

Gastric Cancer

Volumn 14, Issue 3, 2011, Pages 212-218

  Miyashiro, Isao ^a   Furukawa, Hiroshi ^b   Sasako, Mitsuru ^c   Yamamoto, Seiichiro ^d   Nashimoto, Atsushi ^e   Nakajima, Toshifusa ^f   Kinoshita, Taira ^g   Kobayashi, Osamu ^h   Arai, Kuniyoshi ⁱ  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b Sakai City Medical Center   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e NIIGATA CANCER CENTER HOSPITAL   (Japan)

^f CANCER INSTITUTE HOSPITAL   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h KANAGAWA CANCER CENTER   (Japan)

ⁱ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Adjuvant chemotherapy; Intraperitoneal chemotherapy; Randomized clinical trial; Serosa positive gastric cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; FLUOROURACIL; UFT;

ABDOMINAL WALL CLOSURE; ADJUVANT THERAPY; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; GASTRECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; LEUKOPENIA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SEROSA POSITIVE GASTRIC CANCER; SIDE EFFECT; SKIN PIGMENTATION; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COHORT STUDIES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEROUS MEMBRANE; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053910622     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0027-3     Document Type: Article

References (21)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83(1):18-29. (Pubitemid 29409471)
2. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218(5):583-92. (Pubitemid 23339110)
3. Miyashiro I, Takachi K, Doki Y, Ishikawa O, Ohigashi H, Murata K, et al. When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant? World J Surg. 2005;29(9):1131-4. (Pubitemid 41618712)
4. Burke EC, Jr. Karpeh MS, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol. 1998;5(5):411-5. (Pubitemid 28367066)
5. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8(1):1-11. (Pubitemid 12136698)
6. Hiratsuka M, Iwanaga T, Furukawa H, Yasuda T, Nakano H, Nakamori S, et al. Important prognostic factors in surgically treated gastric cancer patients. Gan To Kagaku Ryoho. 1995; 22(5):703-8.
7. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990;19(6):1357-62.
8. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. 1st English ed. Tokyo: Kanehara; 1995.
9. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English edition. Gastric Cancer. 1998; 1(1):10-24.
10. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-20. (Pubitemid 350044801)
11. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999;354(9175):273-7. (Pubitemid 29348734)
12. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21(12):2282-7. (Pubitemid 46621864)
13. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer. 2002;5(1):1-5. (Pubitemid 34496345)
14. Shimoyama M, Fukuda H, Saijo N, Yamaguchi N. Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol. 1998;28(3):158-62. (Pubitemid 128525562)
15. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23(4): 250-7.
16. Sano T, Katai H, Sasako M, Maruyama K. One thousand consecutive gastrectomies without operative mortality. Br J Surg. 2002;89(1):123. (Pubitemid 34031325)
17. Kang Y, Chang H, Zang D, Lee J, Kim T, Yang D, et al. Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: a randomized phase III trial of intra-peritoneal cisplatin and early mitomycin-C plus long-term dox-ifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) (AMC0101) (NCT00296322). J Clin Oncol. 2008;26(15s; ASCO annual meeting abstract LBA4511).
18. Chang H, Kang Y, Min Y, Zang D, Kim G, Yang D, et al. A randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (AMC 0201) (NCT00296335). J Clin Oncol. 2008;26(15s; ASCO annual meeting abstract 4531).
19. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
20. Msika S, Benhamiche AM, Tazi MA, Rat P, Faivre J. Improvement of operative mortality after curative resection for gastric cancer: population-based study. World J Surg. 2000;24(9): 1137-42.
21. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644-51. (Pubitemid 44123569)